Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 996 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Kidney Failure, Chronic, Anemia, Iron-Deficiency
Interventions: iron sucrose injection, USP, sodium ferric gluconate complex in sucrose injection; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Phoenix, Arizona • Alhambra, California • Bell Gardens, California + 9 more

Conditions: Menopause
Interventions: Ashoka Bark and Shatavari, Placebo; Dietary Supplement · Other
Lead sponsor: Vidya USA Corporation; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: GERD
Interventions: Controls & Cases; Other
Lead sponsor: Loren Laine; Other
Eligibility: 21 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Maternal-Fetal Relations, Mother-Child Relations, Maternal Behavior
Interventions: Mindfulness-Based Childbirth and Parenting, Non-Mindfulness-Based Childbirth Class; Behavioral
Lead sponsor: Heidemarie Laurent; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Champaign, Illinois • University Park, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Lunsekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 942 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 75
States / cities: Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 61 more

Conditions: Seasonal Affective Disorder
Interventions: Extended-release bupropion hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 43
States / cities: Anchorage, Alaska • Hamden, Connecticut • Boise, Idaho + 37 more

Conditions: Spinocerebellar Ataxias
Interventions: BHV-4157; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Anxiety Disorders, Depression
Interventions: Individual Behavioral Activation Therapy (IBAT), The PASCET Program for Youth Depressive Disorders, The Coping Cat Program for Youth Anxiety Disorders, 14-week waitlist (WL) condition; Behavioral · Other
Lead sponsor: Rutgers University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Crohn Disease
Interventions: LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more

Conditions: Major Depressive Disorder
Interventions: Ketamine, Psychotherapy; Drug · Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Attention Deficit Hyperactivity Disorder, Parent-Child Relations, Child Behavior, Parenting
Interventions: Promoting Engagement with ADHD Pre-Kindergarteners; Behavioral
Lead sponsor: Lehigh University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Insomnia, Health Adult Subjects, Insomnia Disorder, Heart Health Markers
Interventions: Vinyasa yoga, Gentle yoga, Non-active control; Behavioral · Other
Lead sponsor: Caitlin Cheruka; Other
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Osteopenia
Interventions: Oral calcitonin at dinnertime, Oral placebo at dinnertime, Oral calcitonin at bedtime, Oral placebo at bedtime; Drug
Lead sponsor: Tarsa Therapeutics, Inc.; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Walnut Creek, California • Clearwater, Florida • Bethesda, Maryland + 7 more

Conditions: Improving Fecal Immunochemical Test (FIT) Completion Rates
Interventions: Information pamphlet + social norm driver, Information pamphlet; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 45 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: ALD - Alcoholic Liver Disease
Interventions: Blood draw; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Children, CP (Cerebral Palsy), CP, Cerebral Palsy
Interventions: Brain-Computer Interface (BCI)-HABIT-VR, Hand and Bimanual Intensive Therapy Virtual Reality (HABIT-VR); Device
Lead sponsor: University of Nebraska; Other
Eligibility: 6 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Major Depressive Disorder, Insomnia
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more

Conditions: Type 2 Diabetes Mellitus
Interventions: INT131 besylate, Pioglitazone HCl, Placebo; Drug
Lead sponsor: InteKrin Therapeutics, Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 59
States / cities: Carmichael, California • Los Angeles, California • San Diego, California + 48 more

Conditions: HIV/AIDS
Interventions: Individual Telephone Counseling Intervention, Group Arm, Book Arm; Behavioral · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 50 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Respiratory Depression
Interventions: Fentanyl; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Melanoma
Interventions: Ipilimumab, Chemotherapy; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 4 more

Conditions: Persistent Corneal Epithelial Defect
Interventions: Cenegermin, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more

Conditions: Bipolar Disorder
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 15 Years to 25 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Culver City, California • Lemon Grove, California • Los Angeles, California + 17 more

Search by objective public record fields.

Comparison Between Effects of Two Iron Preparations on Protein in the Urine

Satavari and Ashoka for Menopause (SAM) Study

Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease

Neurobehavioral Effects of Prenatal Mindfulness Training on Maternal Presence and Compassionate Love

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Prevention of Seasonal Affective Disorder

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers

Transdiagnostic Individual Behavioral Activation and Exposure Therapy

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

Project PEAK: Early Intervention for ADHD

Does Style Matter: Comparison of Moderate- to Low-intensity Styles of Yoga

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

Behavioral Nudge in Colorectal Cancer Screening

Comparison of ALD, NASH, and Healthy Control Patients

Training Upper Limbs of Neurodiverse Children by Connecting Brain Activities to a Virtual Reality Based Game

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

Self-Managing HIV and Chronic Disease

Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder